Intellectual Disability ICD-10 Codes: A Clinician’s Guide
In ICD-10, intellectual disability is classified under the block F70–F79, with the numeric suffix indicating severity: F70 (mild), F71 (moderate), F72 (severe), F73 (profound), F78 (other), and F79 (unspecified). These codes describe how a person is affected, graded by intellectual and adaptive functioning. They say nothing about why.
That distinction matters for ordering clinicians. A documented ICD-10 code establishes the clinical picture and supports reimbursement, but the cause often remains open until genetic testing is pursued. Intellectual disability affects roughly 1.8% of children and adolescents worldwide, and identifying the underlying genetic driver changes what families can expect.
Frequently asked questions
What is the ICD-10 code for intellectual disability?
Intellectual disability falls under ICD-10 codes F70 through F79. F70 denotes mild, F71 moderate, F72 severe, and F73 profound intellectual disability. F78 covers other specified forms and F79 covers unspecified cases where severity cannot be assessed.
How is severity assigned in ICD-10?
Severity reflects both IQ and adaptive functioning. Traditional IQ bands are roughly 50–69 (mild), 35–49 (moderate), 20–34 (severe), and below 20 (profound). Current practice weighs adaptive skills and daily support needs more heavily than the IQ number alone.
Does an ICD-10 code identify the cause?
No. ICD-10 codes describe the clinical phenotype and its severity, not the etiology. A code such as F71 documents moderate intellectual disability but does not specify whether a gene variant, chromosomal change, or environmental factor is responsible.
When should genetic testing be considered?
Genetic testing is appropriate for most individuals with unexplained intellectual disability. Professional guidelines position exome or genome sequencing as a first- or second-tier test, because a molecular diagnosis can refine prognosis, recurrence risk, surveillance, and family counseling.
What is the difference between ICD-10 and DSM-5 terms?
ICD-10 uses “intellectual disabilities” (F70–F79), while DSM-5 uses “intellectual developmental disorder.” Both emphasize intellectual and adaptive deficits with onset in the developmental period. The ICD-10 code is what appears on most clinical and billing records.
The F70–F79 codes in detail
The ICD-10 block for intellectual disability divides the condition by severity. Each code pairs an approximate IQ range with an expected level of support in daily life.
- F70 — Mild intellectual disability: IQ roughly 50–69. Many individuals achieve functional independence with support.
- F71 — Moderate intellectual disability: IQ roughly 35–49. Ongoing support with daily tasks is typical.
- F72 — Severe intellectual disability: IQ roughly 20–34. Substantial daily support is required.
- F73 — Profound intellectual disability: IQ below 20. Comprehensive, continuous care is needed.
- F78 — Other intellectual disabilities.
- F79 — Unspecified intellectual disabilities, used when deficits are evident but severity cannot be reliably measured.
Clinically, intellectual disability is defined by limitations in both intellectual and adaptive functioning, typically with an IQ of at most 70, or at least two standard deviations below the population mean. The IQ number anchors the category, but adaptive skills — communication, self-care, social judgment — increasingly guide how clinicians apply these labels.
A phenotype code, not a diagnosis of cause
It helps to think of F70–F79 as describing the surface. Two children sharing an F71 code may have entirely different biology: one a single-gene disorder, another a copy number change, another no identifiable genetic cause at all. The code is the starting point of the diagnostic journey, not its conclusion.
Why the underlying cause matters
Intellectual disability is genetically heterogeneous, meaning hundreds of genes can produce overlapping presentations. A variant in a gene such as MECP2, FMR1, or ARID1B may lead to a recognizable syndrome, each with its own natural history and associated features. Naming the cause often reframes care.
Despite progress, a large share of individuals with intellectual disability — on the order of half in many cohorts — remain without a molecular diagnosis after standard evaluation, as summarized in the 2021 ACMG guidelines. Closing that gap is where sequencing contributes most.
What genetic testing adds
Diagnostic yield varies by cohort and test, but the numbers are meaningful. In a study of 868 children with neurodevelopmental disorders, clinical exome sequencing reached a molecular diagnosis in 27% of cases overall, rising to 34% in those with intellectual disability. A separate validation cohort of 188 patients reported a 34% diagnostic yield, consistent across severity groups.
When clinicians layer tests, yields climb higher. A prospective study combining chromosomal microarray, gene panels, and exome sequencing reached a likely diagnosis in 58% of cases, compared with just 16% from standard clinical evaluation alone. In that cohort, exome sequencing identified a cause in 60% of microarray-negative individuals.
Notably, severity does not reliably predict whether testing will find an answer. One analysis found exome yields of 42% in mild versus 47% in moderate-to-profound intellectual disability — a difference that was not statistically significant. Mild presentations deserve a genetic workup too.
How ICD-10 coding fits the diagnostic pathway
The ICD-10 code and the molecular workup serve different purposes and work best together. The code documents the clinical reality for records, referrals, and reimbursement. The genetic investigation seeks the mechanism behind it.
Professional guidance supports this pairing. The 2021 ACMG guidelines recommend exome or genome sequencing as a first- or second-tier test for unexplained intellectual disability. In practice, that means an F70–F79 code should prompt the question: has the cause been investigated?
When sequencing is negative
A negative exome is not the end. Genome sequencing can detect variants exome testing misses — deep intronic changes, structural rearrangements, and certain deletions. In exome-negative cohorts, genome sequencing adds a further diagnostic yield by uncovering noncoding and structural variants, as reported by Martin et al. (2022). Reanalysis of existing data as knowledge grows is another low-cost path to a delayed diagnosis.
Practical takeaways for ordering clinicians
Use the ICD-10 code to communicate severity and support needs accurately, choosing F79 only when severity genuinely cannot be assessed. Then treat an unexplained code as a trigger for etiologic testing rather than a closed case.
Where available, a broad test such as exome or genome sequencing often outperforms a stepwise series of narrow tests, both in yield and in time to answer. A molecular diagnosis can clarify prognosis, guide surveillance for associated medical issues, inform recurrence risk for the family, and sometimes open the door to targeted management or clinical trials. No genetic test cures intellectual disability, but a precise diagnosis reshapes the care around it.
When the path forward is unclear — which test, how to interpret a variant of uncertain significance, or how to counsel a family — a clinical geneticist or genetic counselor can help tailor the approach to the individual.
* This article is educational and does not replace individualized medical advice. Diagnostic and management decisions should be made with a qualified clinician.
Want to learn more about
3billion's genetic testing?
We'll reply within 1 business day.

Soo-jung Baek
Marketing Manager
I strive to empower the rare disease community by sharing meaningful insights backed by our company’s expertise.





